TNDM (Tandem Diabetes Care Inc.) appears to offer an objective entry for an aggressive swing trade on a break & 60-minute close above the 0.78 resistance level & as such, will be trigger a long entry on any 60-minute candlestick close above the 0.78 level but not higher than the 0.88 level.
TNDM daily Aug 21st
As a penny stock with a questionable fundamental outlook, this should be considered a very aggressive/speculative trade idea. The suggested stop is any move below 0.62, subject to revision based on the actual entry price. Due to the above average gain & loss potential, the suggested beta-adjustment is 0.20-0.30. The first price target is 0.98 with the second & final price target at 1.26.
Tandem recently rallied impulsively following the announcement of a new trial trial for its t:slim X2™ Insulin Pump using Tandem’s predictive low glucose suspend (PLGS) technology. The insulin pump system, which uses an integrated Dexcom G5® Mobile Continuous Glucose Monitor (CGM), is designed to suspend insulin delivery when low blood glucose is predicted and subsequently resume insulin delivery when glucose levels begin to rise. Additional details on that trial can be found in this article while full trial details and site contact information can be found at https://clinicaltrials.gov/ct2/show/NCT03195140.